Active surveillance for incidental renal mass in the octogenarian

Celtik, Kenan; Shah, Paras; Patel, Vinay; Moreira, Daniel; George, Arvin; Iacovelli, Valerio; Alom, Manaf; Ng, Andrew; Herati, Amin S.; Salami, Simpa S.; Bierwiler, Hannah; Schwartz, Michael; Richstone, Lee; Steckel, Joph; Vira, Manish; Kavoussi, Louis R.

doi:10.1007/s00345-016-1961-9

Cited by 13 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The all-cause mortality was 14.6%, while the cancer specific mortality was 3.4%. The OS and CSS at 5 years was 85.7% and 95.6%, respectively [33]. This is similar to survival data in all patients undergoing AS suggesting that AS is an adequate management modality in the octogenarian population despite the more aggressive nature of tumors in this age group, especially when considering their poorer surgical outcomes.…”

Section: Survival On Assupporting

confidence: 80%

Active Surveillance of Small Renal Masses: A Systematic Review

Ellis

Messing

2021

KCA

View full text Add to dashboard Cite

Background: Our goal is to review current literature regarding active surveillance (AS) of small renal masses (SRMs) and identify trends in survival outcomes, factors that predict the need for further intervention, and quality of life (QOL). Methods: We performed a comprehensive literature search in PubMed and EMBASE and identified 194 articles. A narrative summary was performed in lieu of a meta-analysis due to the heterogeneity of selected studies. Results: Seventeen articles were chosen to be featured in this review. Growth rate (GR) was not an accurate predictor of malignancy, although it was the characteristic most commonly used to trigger delayed intervention (DI). The mean 5-year overall survival (OS) of all studies was 73.6% ±1.7% for AS groups. The combined cancer specific survival (CSS) for AS is 97.1% ±0.6% , compared to 98.6% ±0.4% for the primary intervention (PI) groups, (p = 0.038). Conclusions: Short and intermediate-term data demonstrate that AS with the option for DI is a management approach whose efficacy (in terms of CSS) approaches that of PI at 5 years, is cost effective, and prevents overtreatment, especially in patients with significant comorbidities.

show abstract

Section: Survival On Assupporting

confidence: 80%